Search research articles
Contact Us
Filters
Showing results (51-60 of 93) with videos related to
Page
of 10
Sort By:
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Haematologica
|
July 5, 2006
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation
Alessandra Larocca, Giovanna Piaggio, Marina Podestà, et al.
Haematologica
|
July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica
|
April 23, 2026
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Michela Cumerlato, Monica Maccagno, María Labrador, et al.
Blood
|
August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Experimental Hematology & Oncology
|
August 10, 2023
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, et al.
Cancer
|
December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella, Paola Omedé, Stefano Spada, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Stem Cell Research & Therapy
|
April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
Pellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
British Journal of Haematology
|
October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 93) with videos related to
Sort By:
Page
of 10
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Haematologica
|
July 5, 2006
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation
Alessandra Larocca, Giovanna Piaggio, Marina Podestà, et al.
Haematologica
|
July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica
|
April 23, 2026
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Michela Cumerlato, Monica Maccagno, María Labrador, et al.
Blood
|
August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Experimental Hematology & Oncology
|
August 10, 2023
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, et al.
Cancer
|
December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Manuela Gambella, Paola Omedé, Stefano Spada, et al.
Blood
|
May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Stem Cell Research & Therapy
|
April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
Pellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
British Journal of Haematology
|
October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Page
of 10